Investors had “incredibly high” expectations around the Phase 3 data for the drugmaker’s experimental cancer treatment.
Summary from the MarketWatch news feed. Copyright belongs to MarketWatch.
Opens in a new tab, so Investz stays open.
Headlines and summaries come from publishers’ public news feeds and are shown with attribution and a link to the original. Investz does not write or endorse them and they are not investment advice. Disclosures.